DisCoVeRy: Trial of Treatments for COVID-19 in Hospitalized Adults

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT04315948
Collaborator
(none)
2,416
Enrollment
72
Locations
7
Arms
35.3
Anticipated Duration (Months)
33.6
Patients Per Site
1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be evaluated, clinical trial to evaluate the safety and efficacy of possible therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The study is a multi-centre/country trial that will be conducted in various sites in Europe with Inserm as sponsor. The study will compare different investigational therapeutic agents to a control group managed with the SoC including corticosteroids and anticoagulants. There will be interim monitoring to allow early stopping for safety and to introduce new therapies as they become available. If one therapy proves to be superior to others in the trial, this treatment may become part of the SoC for comparison(s) with new experimental treatment(s).

In previous versions of the DisCoVeRy protocol, remdesivir, lopinavir/ritonavir with or without interferon ß-1a and hydroxychloroquine were evaluated as potential treatments for COVID-19. These treatments have been discontinued based on analyses review by both DSMC/DSMB, the Solidarity Executive Group and the DisCoVeRy steering committee.

This version of the protocol, therefore, describes a randomized blinded placebo-controlled trial among adults (≥18-year-old) hospitalized for COVID-19 that randomly allocates them (1:1 ratio) between 2 arms: SoC + placebo versus SoC + AZD7442.

Randomization will be stratified by region (according to the administrative definition in each country), antigenic status (positive or negative) obtained from the result of a rapid antigen test on nasopharyngeal swab performed at enrolment and vaccination initiation (yes or no).

The primary analyses will be conducted on patients with antigen-positive results. A positive antigenic test is evidence of high viral shedding consistent with a recently started or uncontrolled infection. Overall, the number of antigen-negative patients will be at most 30% of all included subjects. The number of patients with vaccination (partly or fully) will be limited to 20% of all participants, split evenly between antigen positive and antigen negative patients (i.e. vaccinated patients can make up at most 20% of antigene positive patients and 20% of antigene negative patients). Sensitivity analyses will be performed in all patients, stratified by antigenic status and vaccination initiation.

A global independent data and safety monitoring board (DSMB) monitors interim data to make recommendations about early study closure or changes to conduct, including adding or removing treatment arms. However, the current version of the protocol does not allow for efficacy or futility analysis, and the ability to add trial arms will be limited by the study being blinded and placebo-controlled during the investigation of AZD7442.

Condition or DiseaseIntervention/TreatmentPhase
Phase 3

Detailed Description

DisCoVeRy is a randomized controlled trial among adults (≥18-year-old) hospitalized for COVID-19. This study is an adaptive, randomized, open or blinded, depending on the drug to be evaluated, clinical trial to evaluate the safety and efficacy of possible therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The study is a multi-centre/country trial that will be conducted in various sites in Europe with Inserm as sponsor. The study will compare different investigational therapeutic agents to a control group managed with the SoC including corticosteroids and anticoagulants. There will be interim monitoring to allow early stopping for safety and to introduce new therapies as they become available. If one therapy proves to be superior to others in the trial, this treatment may become part of the SoC for comparison(s) with new experimental treatment(s).

In previous versions of the DisCoVeRy protocol, remdesivir, lopinavir/ritonavir with or without interferon ß-1a and hydroxychloroquine were evaluated as potential treatments for COVID-19. These treatments have been discontinued based on analyses review by both DSMC/DSMB, the Solidarity Executive Group and the DisCoVeRy steering committee.

This version of the protocol, therefore, describes a randomized blinded placebo-controlled trial among adults (≥18-year-old) hospitalized for COVID-19 that randomly allocates them (1:1 ratio) between 2 arms: SoC + placebo versus SoC + AZD7442.

Randomization will be stratified by region (according to the administrative definition in each country), antigenic status (positive or negative) obtained from the result of a rapid antigen test on nasopharyngeal swab performed at enrolment and vaccination initiation (yes if at least one injection of any vaccine against SARS-CoV-2 was reveived prior to enrolment whatever the delay or no).

The primary analyses will be conducted on patients with antigen-positive results. A positive antigenic test is evidence of high viral shedding consistent with a recently started or uncontrolled infection. Overall, the number of antigen-negative patients will be at most 30% of all included subjects. The number of patients with vaccination (partly or fully) will be limited to 20% of all participants, split evenly between antigen positive and antigen negative patients (i.e. vaccinated patients can make up at most 20% of antigene positive patients and 20% of antigene negative patients). Sensitivity analyses will be performed in all patients, stratified by antigenic status and vaccination initiation.

A global independent data and safety monitoring board (DSMB) monitors interim data to make recommendations about early study closure or changes to conduct, including adding or removing treatment arms. However, the current version of the protocol does not allow for efficacy or futility analysis, and the ability to add trial arms will be limited by the study being blinded and placebo-controlled during the investigation of AZD7442.

All subjects will undergo a series of efficacy and safety assessments, including laboratory assays.

Subjects will be assessed at baseline, and at Days 3, 8 and 15 while hospitalized. Patients will be contacted by phone at Day 15 for evaluation of the Primary Endpoint if they have been discharged prior to Day 15-, and 14-days following hospital discharge for efficacy assessment.

Further follow-up assessments will be organized at Days 29, 90, 180, 365 and 456.

If discharged from the hospital, days 29 and 90 assessments will be organized as outpatients' consultations for all. For Days 180 and 365 assessments, a subset of 25% of patients enrolled in centers with available resources and selected at Day 90 will be evaluated during a medical consultation, while the other will be contacted by phone. For Day 456, all patients will be contacted by phone.

Nasopharyngeal swabs (NP) or lower respiratory tract samples will be obtained at baseline (Day 1 pre-treatment) and at Days 3, 8, 15 (while hospitalized) and 29 (while hospitalized or, if discharged from the hospital, in the outpatient setting).

Blood samples will be obtained at baseline (Day 1 pre-treatment) and at Days 3, 8, 15 (while hospitalized), at Days 29 and 90, and at Days 180 and 365 (for the subset of patients evaluated during a medical consultation at these times).

Thoracic computed tomography (CT)-scan will be obtained at baseline, depending on the centre's imagery capacities.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2416 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
From March 22, 2020 to May 24, 2020, the study randomized participants 1:1:1:1:1 to standard of care alone (control) or with investigational product added. From May 24, 2020 to June 29, 2020, the study randomized participants 1:1:1:1 to standard of care alone (control) or with investigational product added. From June 29, 2020 to January 19,2021, the study randomized participants 1:1 to standard of care alone (control) or with investigational product added. Since April, 2021, the study will randomize participants 1:1 to standard of care with placebo (control) or standard of care with investigational product added.From March 22, 2020 to May 24, 2020, the study randomized participants 1:1:1:1:1 to standard of care alone (control) or with investigational product added. From May 24, 2020 to June 29, 2020, the study randomized participants 1:1:1:1 to standard of care alone (control) or with investigational product added. From June 29, 2020 to January 19,2021, the study randomized participants 1:1 to standard of care alone (control) or with investigational product added. Since April, 2021, the study will randomize participants 1:1 to standard of care with placebo (control) or standard of care with investigational product added.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
the treatment arm SOC + hydroxychloroquine has been ceased since May 24, 2020; the treatment arm SOC + lopinavir / Ritonavir and lopinavir / ritonavir + interferon ß-1a has been ceased since June 29, 2020 the treatment arm SOC + remdesivir has been ceased since January 19, 2021 the treatment arm SOC + AZD7442
Primary Purpose:
Treatment
Official Title:
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Actual Study Start Date :
Mar 22, 2020
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

ArmIntervention/Treatment
Experimental: Remdesivir

Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course. n=475

Drug: Remdesivir
The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.

Other: Standard of care
Standard of care

Experimental: Lopinavir/ritonavir (stopped on June 29, 2020)

Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube. n=620

Drug: Lopinavir/ritonavir
The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the "a" logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).

Other: Standard of care
Standard of care

Experimental: Lopinavir/ritonavir plus Interferon ß-1a (stopped on June 29)

Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube. Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6). n=620

Drug: Lopinavir/ritonavir
The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the "a" logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).

Drug: Interferon Beta-1A
IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.

Other: Standard of care
Standard of care

Experimental: Hydroxychloroquine (stopped on May 24, 2020)

Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 days n=620

Drug: Hydroxychloroquine
Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).

Other: Standard of care
Standard of care

Active Comparator: Standard of care alone

Standard of care alone before March, 2021.

Other: Standard of care
Standard of care

Experimental: AZD7442

Participants randomized to the AZD7442 group will receive a total dose of 600 mg AZD7442 via a co-administered (300 mg AZD8895 and 300 mg AZD1061) single IV infusion on Day 1. n=620

Other: Standard of care
Standard of care

Drug: AZD7442
AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.

Active Comparator: Standard of care with placebo

Standard of care with placebo since April, 2021 n=620

Other: Standard of care
Standard of care

Other: Placebo
Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.

Outcome Measures

Primary Outcome Measures

  1. Percentage of subjects reporting each severity rating on a 7-point ordinal scale [Day 15]

    Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death.

Secondary Outcome Measures

  1. Status on an ordinal scale [Days 29, 90, 180 and 365]

    Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale

  2. National Early Warning Score 2 (NEWS-2 score) [Days 3, 8, 15, and 29]

    Change from baseline in NEWS-2.

  3. Number of oxygenation free days in the first 28 days [29 days]

  4. Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial. [29 days]

  5. Ventilator free days in the first 28 days [29 days]

  6. Incidence of new mechanical ventilation use during the trial. [29 days]

  7. Need for mechanical ventilation or death by Day 15 [Day 15]

    Proportion of patients with mechanical ventilation or death at day 15

  8. Hospitalization [29 days]

    Time to hospital discharge (days).

  9. Mortality [In hospital, Days 29, 90, 180, 365, 456]

    Rate of mortality

  10. Occurrence of new hospitalization [Days 90, 180 and 365]

  11. Occurrence of confirmed re-infection with SARS-CoV-2 [Days 90, 180 and 365]

  12. Cumulative incidence of serious adverse events (SAEs) [29 days]

  13. Cumulative incidence of Grade 1- 2 hypersensitivity- related and infusion related AEs until D29 visit [29 days]

  14. Cumulative incidence of Grade 3 and 4 adverse events (AEs) [29 days]

  15. Number of participants with a discontinuation or temporary suspension of study drugs (for any reason) [29 days]

  16. Cumulative incidence of AEs of Special Interest [29 days]

Other Outcome Measures

  1. Percent of subjects with SARS-CoV-2 detectable in nasopharyngeal sample [Days 3, 5, 8, 11, 15, 29]

  2. Quantitative SARS-CoV-2 virus in nasopharyngeal sample [Days 3, 5, 8, 11, 15, 29]

  3. Quantitative SARS-CoV-2 virus in blood [Days 3, 8]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Adult ≥18 years of age at the time of enrolment

  2. Hospitalized patients with any of the following criteria:

  3. the presence of pulmonary rales/crackles on clinical exam OR

  4. SpO2 ≤ 94% on room air OR

  5. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation

  6. A time between onset of symptoms and randomization of less than 11 days

  7. A positive SARS-CoV-2 PCR performed on a NP swab within the 5 days preceding randomization

  8. The result of a rapid antigen test performed on a NP swab within the 6 hours preceding randomization

  9. Contraceptive use by men or women.

  10. Male participants: Contraception for male participants is required; to avoid the transfer of any fluids, all male participants must use a condom from Day 1 and agree to continue for 90 days following administration of IMP.

  11. Female participants: Women of child-bearing potential must agree to use contraception for 365 days following administration of IMP

Exclusion Criteria:
  1. Refusal to participate expressed by patient or legally authorized representative

  2. Need for invasive mechanical ventilation and/or ECMO at the time of enrolment

  3. Spontaneous blood ALT/AST levels > 5 times the upper limit of normal

  4. Glomerular filtration rate (GFR) < 15 mL/min or requiring maintenance dialysis

  5. Pregnancy or breast-feeding

  6. Anticipated transfer to another hospital, which is not a study site within 72 hours following randomization

  7. Known history of allergy or reaction to any component of the study drug formulation.

  8. Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal or polyclonal antibodies.

  9. Any prior receipt of investigational or licensed other mAb/biologic indicated for the prevention of SARS-CoV-2 infection or COVID-19, and for those not vaccinated, expected receipt of vaccine in the 30 days following hospital discharge, according to current recommendation in each country.

  10. Any medical condition which, in the judgment of the investigator, could interfere with the interpretation of the trial results or that preludes to protocol adherence.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1Medizinische Universität InnsbruckInnsbruckAustria6020
2Kepler Universitätsklinikum LinzLinzAustria
3Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen PrivatuniversitätSalzburgAustria5020
4Hôpital Erasme - Cliniques universitaires de BruxellesBrusselsBelgium1070
5Hôpital Saint LucBrusselsBelgium1200
6CHU BrugmannBrusselsBelgium
7Hôpital La CitadelleLiègeBelgium4000
8Pôle Hospitalier Jolimont / site de Mons-WarquigniesMonsBelgium
9Fakultní nemocnice u sv. Anny v BrněBrnoCzechia
10Centre Hospitalier Universitaire Amiens-PicardieAmiensFrance80054
11Centre Hospitalier Regional Metz-ThionvilleArs-LaquenexyFrance57085
12Centre Hospitalier Régional Universitaire de BesançonBesançonFrance25000
13Centre Hospitalier Universitaire de BordeauxBordeauxFrance33000
14CHU APHP Ambroise-ParéBoulogne-BillancourtFrance
15Centre Hospitalier Andrée RosemonCayenneFrance97306
16CHU Clermont-FerrandClermont-FerrandFrance
17Hospices CivilColmarFrance
18APHP - hôpital Henri-MondorCréteilFrance94010
19Centre Hospitalier Universitaire Dijon-BourgogneDijonFrance21000
20Centre Hospitalier Universitaire de MartiniqueFort De FranceFrance97261
21AP-HP Hôpital BicêtreKremlin-BicêtreFrance94270
22Centre Hospitalo-Universitaire de GrenobleLa TroncheFrance38700
23Centre hospitalier de VersaillesLe ChesnayFrance78157
24Centre Hospitalier Régional Universitaire de LilleLilleFrance59000
25Hospices Civils de LyonLyonFrance69000
26Centre Hospitalier de Mont de MarsanMont-de-MarsanFrance40024
27Centre Hospitalier Universitaire de MontpellierMontpellierFrance34000
28Groupe Hospitalier de la Région de Mulhouse Sud AlsaceMulhouseFrance68100
29Centre Hospitalier Régional et Universitaire de NancyNancyFrance54000
30Centre Hospitalier Universitaire de NantesNantesFrance44000
31Centre Hospitalo-Universitaire de NiceNiceFrance06000
32CHU NîmesNîmesFrance
33APHP - Hôpital LariboisièreParisFrance75010
34APHP - Hôpital Saint LouisParisFrance75010
35APHP - Hôpital Saint AntoineParisFrance75012
36APHP - Hôpital Universitaire Pitié SalpêtrièreParisFrance75013
37APHP - Hôpital CochinParisFrance75014
38Hôpital Paris Saint-Joseph et Marie LannelongueParisFrance75014
39APHP - Hôpital NeckerParisFrance75015
40APHP- Hôpital Européen Georges-PompidouParisFrance75015
41APHP - Hôpital Bichat Claude BernardParisFrance75018
42APHP - Hôpital TenonParisFrance75020
43CHU PoitiersPoitiersFrance
44CH CornouailleQuimperFrance
45CHU de ReimsReimsFrance51100
46Centre Hospitalier Universitaire de RennesRennesFrance35033
47Hopital DELAFONTAINESaint-DenisFrance93200
48Hôpital d'Instruction des Armées BEGINSaint-MandéFrance94160
49Centre Hospitalier Universitaire de Saint EtienneSaint-ÉtienneFrance42055
50Centre Hospitalier Régional Universitaire de StrasbourgStrasbourgFrance67000
51Centre Hospitalier Universitaire de ToulouseToulouseFrance31000
52Centre Hospitalier Universitaire de ToulouseToulouseFrance31300
53Centre Hospitalier de TourcoingTourcoingFrance59208
54Centre Hospitalier Universitaire de ToursToursFrance37000
55CH Bretagne AtlantiqueVannesFrance56000
56CH Bretagne AtlantiqueVannesFrance
57Centre Hospitalier Annecy GenevoisÉpagnyFrance74370
58Evaggelismos General HospitalAthensGreece
59General University Hospital of PatrasPatrasGreece
60hospital Saint JamesDublinIreland
61Centre Hospitalier LuxembourgLuxembourgLuxembourgL-1210
62Hôpitaux Robert SchumanLuxembourgLuxembourgL-2450
63Akershus Unniversity HospitalOsloNorway
64Lovisenberg Diaconal HospitalOsloNorway
65Oslo University HospitalOsloNorway
66Bienganski HospitalŁódźPoland
67Hospital de Abrantes (CHMT)AbrantesPortugal
68Hospital de CascaisCascaisPortugal
69CHULN- Hospital de Santa MariaLisboaPortugal
70CHULN- Hospital de Santa MariaLisboaPortugal
71Centro Hospitalar Universitário de São João, EPEPortoPortugal
72Martin University HospitalMartinSlovakia

Sponsors and Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Investigators

  • Study Chair: Florence Ader, MD, Hospices Civils de Lyon

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier:
NCT04315948
Other Study ID Numbers:
  • C20-15
  • 101015736
First Posted:
Mar 20, 2020
Last Update Posted:
Mar 21, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 21, 2022